SynthesisEuropean journal of clinical pharmacology2024
Is atezolizumab plus bevacizumab as first-line therapy for unresectable hepatocellular carcinoma superior to lenvatinib? a systematic review and meta‑analysis.
Gang Zhu et al.PubMed ↗Publisher ↗
No numbers read from the abstract.